ELTX

NASDAQ 已收盘

Elicio Therapeutics

1.45 USD
▼-0.05-3.33%
盘后 1.51 0.00%
2026-11-20
市值
$41.05M
市盈率
—
EPS
-1.80
股息率
—
52 周区间
1.25 – 16.00
成交量
231.62K
Beta
2.00
目标价
13.00
52W 低 1.2552W 高 16.00
价格走势

公司简介

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targe...